Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

171.73 +3.97 (+2.37%)
Official Closing Price Updated: 4:10 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9
...
70 71 Next >
Is Eli Lilly a Buy? Analyst Confidence Grows for 2025
Eli Lilly's price pullback is an opportunity worth 25%, with analysts' sentiment firming around the $1000 level. New highs are likely by early 2025. 
Via MarketBeat
Merck vs. Bristol-Myers: Analyst Views Differ After Q3 Earnings
After strong earnings reports, Merck may be a better choice than Bristol-Meyers in the short term - but both may present a challenge for buy-and-hold investors. 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
Here's How Much $100 Invested In AbbVie 10 Years Ago Would Be Worth Today
Via Benzinga
High-Yield AbbVie Gains Momentum: A 20% Upside Is in Sight
High-yielding AbbVie is on track for another 20% gain, which could happen by the end of the year. Analysts are raising their targets, leading to higher prices. 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
AbbVie Dividend Increase
On 30 October, AbbVie (ABBV) increased its quarterly dividend by 5.81%, from $1.55 to $1.64 per share. 
Via Talk Markets
Price Over Earnings Overview: AbbVie
Via Benzinga
Market Analysis: AbbVie And Competitors In Biotechnology Industry
Via Benzinga
AbbVie's Options Frenzy: What You Need to Know
Via Benzinga
Bristol Myers Squibb Stock Gets Relative Strength Rating Upgrade
On Friday, Bristol Myers Squibb stock earned an upgrade to its Relative Strength (RS) Rating, from 62 to 79. 
Via Investor's Business Daily
Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review
The major indexes declined, but haven't fallen apart. 
Via Investor's Business Daily
5 Dividend Stocks to Double Up on Right Now -- Plus Some Dividend ETFs
It's hard to beat the power of dividend-paying stocks. They have outperformed non-payers significantly. 
Via The Motley Fool
Forecasting The Future: 11 Analyst Projections For AbbVie
Via Benzinga
Check Out What Whales Are Doing With ABBV
Via Benzinga
AbbVie’s Dividend Isn’t As Scary As It Looks
AbbVie currently pays shareholders a quarterly dividend of $1.55 per share, which gives the stock a 3.3% yield on the current price. 
Via Talk Markets
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio. 
Via Benzinga
Wall Street Mixed, Semiconductors Tumble As AMD Disappoints, Alphabet Rallies, SMCI Plummets: What's Driving Markets Wednesday?
Wall Street experienced a mixed trading session on Wednesday as investors weigh a batch of corporate earnings and fresh economic data. 
Via Benzinga
AbbVie (ABBV) Q3 2024 Earnings Call Transcript
ABBV earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
AbbVie Tops Q3 Expectations As Skyrizi, Rinvoq Drive Growth
AbbVie's Q3 earnings surpassed expectations with $3.00 EPS and $14.46 billion in revenue. Skyrizi and Rinvoq led growth; AbbVie also raised 2024 EPS guidance. 
Via Benzinga
AbbVie Has A New Cash Cow As Humira Bows To Skyrizi In Third-Quarter Beat
AbbVie easily beat third-quarter expectations and raised its earnings outlook for the year. 
Via Investor's Business Daily
3 Dividend Growth Stocks to Buy and Never Sell
These 3 dividend growth stocks have crushed the market and show no signs of slowing down. 
Via The Motley Fool
Biotech Momentum Trades For The Q4 Rally
The biotech sector made an interim peak in late February followed by an active summer in very choppy trading. 
Via Talk Markets
AbbVie Chart Reflects Bearish Signals Ahead Of Q3 Earnings
AbbVie (ABBV) reports Q3 earnings Wednesday. The acquisition of Aliada Therapeutics may boost its Alzheimer's portfolio and stock, currently up 33.68% YTD. 
Via Benzinga
Sweetgreen, Tesla, Digital Realty Trust And A Health Care Stock On CNBC's 'Final Trades'
Sweetgreen shares closed at $37.48 during Friday's session. Analysts also discuss Tesla, AbbVie and Digital Realty Trust on 'Final Trades' 
Via Benzinga
What Lies In Store For Healthcare ETFs In Q3 Earnings?
The healthcare sector has performed well in recent months, driven by the booming weight-loss drug treatment segment. As such, various healthcare ETFs have benefited. 
Via Talk Markets
Topics ETFs
3 Dividend Growth Stocks You Can Buy and Hold Forever
These healthcare stocks have fantastic dividend track records. 
Via The Motley Fool
3 High-Yielding Dividend Stocks That Can Be Ideal Buys for Retirees
These stocks yield between 2.8% and 3.3% in dividends. 
Via The Motley Fool
Beat the Nasdaq With This Cash-Gushing Dividend Stock
The company is performing well despite recently losing its biggest growth driver. 
Via The Motley Fool
3 Simple Vanguard ETFs to Buy With $1,000 and Hold for a Lifetime
These three Vanguard ETFs are worth considering for the long term. 
Via The Motley Fool
Topics ETFs
Healthcare Sector Update: Choppy Days Are Here Again As Yields Rise
There has been a shift in healthcare stock performance by sub-sector which should be confirmed as we move through the Q3 earnings cycle. 
Via Talk Markets
3 Growth Stocks That Could Be Bargain Buys Right Now
These stocks trade at less than 20 times their estimated future profits. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
70 71 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.